You are here
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
NCT00004861
Last updated on
February 22, 2019
About this Study
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced pancreatic cancer.
Eligibility criteria
Condition
Pancreatic Cancer
Sex
Females and Males
Age
18 + years
Inclusion criteria
Show details
Exclusion criteria
Show details
NCT00004861
Pfizer
Completed
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Based on your search, you may also be interested in
Pancreatic Cancer
NCT00004861
All Genders
18+
Years
Multiple Sites
Pancreatic Cancer, Non-Small Cell Lung Cancer, Cancer
NCT03637491
All Genders
18+
Years
Multiple Sites
Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1), Advanced Glioblastoma Multiforme (Part 1)
NCT00959946
All Genders
18+
Years
Multiple Sites
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
BY PHONE
Pfizer Clinical Trials Contact Center
1-800-718-1021